Skip to main content
Equibles

HELP · Cybin Inc.

Track HELP — free

Use HELP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HELP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.97 +0.13 (+1.01%) At close · Sep 11
Rebalance outlook locked
Market Cap
$947.59M
Shares
73.06M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.97 Open$13.27 Day$12.61–13.52 52W close$3.87–13.99 Avg vol 30d1.8M Short int3.0M · 4.1% float · 2.0d Short vol32% Last earningsNov 13, 2025 DataSep 2024–Sep 2026

Raw chart and full-history price indicators begin at the captured split on Sep 19, 2024; bars on opposite sides are not compared.

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+115.8%
Trailing year
Short interest
4.1%
Latest settlement · 2.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Very Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +88%
above
Price vs 50-day avg +32%
above
RSI (14) 60
neutral
MACD trend Negative
52-week position 90%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +13%
trailing
6-month return +181%
trailing
YTD return +59%
this year
Relative strength +163%
vs S&P · 6-mo
Sentiment
smart money
Very Bullish
Trend (MA cross) No cross
50d $10 › 200d $7 — 50d above 200d
Institutional flow Accumulating
+21% holders QoQ · +28 funds added
Insider flow Accumulating
Net +$8.3M over 90 days · 0% sells
Short interest Falling
4.13% of float · ▼ -5.6% MoM · 2.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
99 holders — near 2-yr high, broad support
Squeeze score 64
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 84%
annualized · 1-yr
Max drawdown −56%
past year
ATR 6.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+88% Bullish
Price vs 50-day avg
+32% Bullish
RSI (14)
60 Neutral
MACD trend
Negative Bearish
52-week position
90% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) No cross
50d $10 › 200d $7 — 50d above 200d
Institutional flow Accumulating
+21% holders QoQ · +28 funds added
Insider flow Accumulating
Net +$8.3M over 90 days · 0% sells
Short interest Falling
4.13% of float · ▼ -5.6% MoM · 2.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
99 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $13 · 90% Range high $14
vs 200-day avg +88% vs 50-day avg +32%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HELP
Cybin Inc.
this stock
$947.59M +58.6% — — 4.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
99
% held
42.2%
Net QoQ
+6.1M sh
Top holder
Venrock Adviser, LLC
Held Float
View
Held by Funds
Fund positions
5
View
Short & Settlement
Short Interest Falling
Shares short
3.0M
Days to cover
2.0d
Change
-178.4K sh
View
Short Volume
Short vol %
32%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
626
Value
$7.2K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
50.2%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$8.3M
Buyers / Sellers
2 / 0
Buyers Sellers
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 10, 2026
This year
35
View
Exempt Offerings
Offering
$262.0K
Filed
Sep 1, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 12, 2026
View

Performance

Raw-price comparisons begin at the captured split on Sep 19, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
HELP +10.2% +13.3% +180.7% +10.3% +58.6%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY +11.4% +15.0% +162.9% +10.7% +46.5%
Key facts CIK 1833141 CUSIP 23256X407 13F (30d) 49 filings 49 filers Visit website Investor relations